255 related articles for article (PubMed ID: 29084753)
1. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.
Zasowski EJ; Murray KP; Trinh TD; Finch NA; Pogue JM; Mynatt RP; Rybak MJ
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084753
[TBL] [Abstract][Full Text] [Related]
2. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
[TBL] [Abstract][Full Text] [Related]
3. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
[TBL] [Abstract][Full Text] [Related]
4. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
5. Establishment of an AUC
Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children.
Le J; Ny P; Capparelli E; Lane J; Ngu B; Muus R; Romanowski G; Vo T; Bradley J
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):e109-16. PubMed ID: 26582878
[TBL] [Abstract][Full Text] [Related]
7. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
[TBL] [Abstract][Full Text] [Related]
8. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
Lodise TP; Lomaestro B; Graves J; Drusano GL
Antimicrob Agents Chemother; 2008 Apr; 52(4):1330-6. PubMed ID: 18227177
[TBL] [Abstract][Full Text] [Related]
9. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.
Bosso JA; Nappi J; Rudisill C; Wellein M; Bookstaver PB; Swindler J; Mauldin PD
Antimicrob Agents Chemother; 2011 Dec; 55(12):5475-9. PubMed ID: 21947388
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin AUC
Brandon HH; Burgess DS; Wallace KL; Autry EB; Olney KB
Pharmacotherapy; 2024 Apr; 44(4):294-300. PubMed ID: 38533999
[TBL] [Abstract][Full Text] [Related]
12. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records.
Chen Q; Wan J; Shen W; Lin W; Lin X; Huang Z; Lin M; Chen Y
Pediatr Neonatol; 2022 May; 63(3):247-254. PubMed ID: 35190273
[TBL] [Abstract][Full Text] [Related]
13. Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients.
Bel Kamel A; Bourguignon L; Marcos M; Ducher M; Goutelle S
Ther Drug Monit; 2017 Feb; 39(1):83-87. PubMed ID: 27861313
[TBL] [Abstract][Full Text] [Related]
14. Impact of Area Under the Concentration-Time Curve-Guided Monitoring on Vancomycin Nephrotoxicity and Treatment Outcomes in Methicillin-Resistant
Kim YR; Chun HJ; Heo JY; Yoo JS; Choi YH; Kim EJ
Curr Ther Res Clin Exp; 2022; 97():100687. PubMed ID: 36439399
[TBL] [Abstract][Full Text] [Related]
15. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
McClure S; McElroy L; Gugkaeva Z
Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
[TBL] [Abstract][Full Text] [Related]
16. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study.
Hall RG; Hazlewood KA; Brouse SD; Giuliano CA; Haase KK; Frei CR; Forcade NA; Bell T; Bedimo RJ; Alvarez CA
BMC Pharmacol Toxicol; 2013 Feb; 14():12. PubMed ID: 23402420
[TBL] [Abstract][Full Text] [Related]
17. Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?
Johnston MM; Huang V; Hall ST; Buckley MS; Bikin D; Barletta JF
Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115442. PubMed ID: 34192639
[TBL] [Abstract][Full Text] [Related]
18. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients.
Hashimoto N; Kimura T; Hamada Y; Niwa T; Hanai Y; Chuma M; Fujii S; Matsumoto K; Shigemi A; Kawamura H; Takahashi Y; Takesue Y
J Glob Antimicrob Resist; 2021 Dec; 27():12-19. PubMed ID: 34371241
[TBL] [Abstract][Full Text] [Related]
19. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
Suzuki Y; Kawasaki K; Sato Y; Tokimatsu I; Itoh H; Hiramatsu K; Takeyama M; Kadota J
Chemotherapy; 2012; 58(4):308-12. PubMed ID: 23147106
[TBL] [Abstract][Full Text] [Related]
20. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
